Ascelia Pharma ABOSTO:ACE +2.67%28 Current Ratio is 2.80 as of Mar. 2026, which is 66% below its 10-year median of 8.34. GuruFocus rates OSTO:ACE with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Ascelia Pharma AB ranks worse than 59.6% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ascelia Pharma AB's current ratio for the quarter that ended in Mar. 2026 was 2.80.
Ascelia Pharma AB has a current ratio of 2.80. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ascelia Pharma AB's Current Ratio or its related term are showing as below:
OSTO:ACE'
s Current Ratio Range Over the Past 10 Years
Min: 1 Med: 8.34 Max: 23.69
Current: 2.8
During the past 9 years, Ascelia Pharma AB's highest Current Ratio was 23.69. The lowest was 1.00. And the median was 8.34.
OSTO:ACE's Current Ratio is ranked worse than 59.6% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs OSTO:ACE: 2.80
Ascelia Pharma AB (OSTO:ACE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ascelia Pharma AB Current Ratio Related Terms
Ascelia Pharma AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Ascelia Pharma AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ACE vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Ascelia Pharma AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascelia Pharma AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ascelia Pharma AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascelia Pharma AB (OSTO:ACE) has a Current Ratio of 2.80 as of Mar. 2026. This is 66% below median its historical median of 8.34. Over the past decade, Ascelia Pharma AB's Current Ratio has ranged from 1.00 to 23.69. According to the industry distribution chart, Ascelia Pharma AB ranks #844 out of 1416 companies in the Biotechnology industry, placing it in the top 59.6%.
Is Ascelia Pharma AB's Current Ratio too high?
Ascelia Pharma AB's current Current Ratio of 2.80 is 66% below median its 10-year median of 8.34. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 23.69. The Biotechnology industry median Current Ratio is 3.89. Ascelia Pharma AB's value of 2.80 is 27.9% below this industry median. Based on the distribution chart, Ascelia Pharma AB ranks #844 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascelia Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #844 out of 1416 companies for Current Ratio. This places Ascelia Pharma AB in the lower half of its industry. The industry median Current Ratio is 3.89. Ascelia Pharma AB's value of 2.80 is 27.9% below this benchmark. Historically, Ascelia Pharma AB's own Current Ratio has ranged from 1.00 to 23.69 over the past decade. While the company's 10-year median is 8.34 vs. the industry median of 3.89, Ascelia Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascelia Pharma AB's current Current Ratio of 2.80 is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascelia Pharma AB's current Current Ratio is 2.80, which is 66% below median its own 10-year median of 8.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Current Ratio of 2.80. The current Current Ratio is 2.80, which is 66% below median its 10-year median of 8.34 and 27.9% below the Biotechnology industry median of 3.89. Ascelia Pharma AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Current Ratio is 2.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
28GF Score
Get the complete analysis for OSTO:ACE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACE has been successfully added to your 
